A hybrid ligand method for androgen receptor measurement

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Androgen receptor (AR) assays are crucial for understanding hormone-dependent conditions.
• Existing AR assays face challenges due to ligand cross-reactivity with sex hormone-binding globulin (SHBG) and progesterone receptors (PgR).
• Commonly used ligands like [3H]dihydrotestosterone ([3H]DHT) and [3H]methyltrienolone ([3H]R1881) exhibit non-specific binding, complicating accurate AR concentration measurement.

Purpose of the Study:

• To develop a novel, reliable method for quantifying AR in the presence of interfering proteins like SHBG and PgR.
• To address the limitations of current AR assay techniques, particularly concerning ligand cross-reactivity.
• To investigate the prevalence of AR in human colorectal carcinomas.

Main Methods:

• Development of a hybrid ligand assay utilizing [3H]R1881 as a labeled tracer and DHT as an unlabeled competitor.
• The assay is designed to specifically measure AR binding, mitigating interference from SHBG and PgR.
• Application of the developed assay to analyze AR expression in human colorectal carcinoma samples.

Main Results:

• The hybrid ligand method successfully measured AR in the presence of SHBG and PgR.
• The assay demonstrated improved specificity compared to traditional methods.
• Androgen receptor (AR) was detected in 20% of the analyzed human colorectal carcinomas.

Conclusions:

• The developed hybrid ligand assay offers a more accurate approach for AR quantification.
• This method overcomes significant limitations of existing AR assays.
• The findings indicate a notable prevalence of AR in colorectal cancer, suggesting potential therapeutic implications.